Kancera provides operational update in connection with the interim report for the first quarter of 2022


This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.

Kancera AB (publ) today publishes the interim report for the period January – March 2022. The complete report is published today on the company’s website.

“On May 1, we welcomed Peter Selin to the company as Executive Vice President Corporate Development responsible for business development, strategic partnerships and out-licensing. Peter is member of the management team and will play an important role in the continued value building of Kancera.

We are now looking forward to a continued strong recruitment of patients for the cardiac study in England and the preparatory steps for a clinical study of fractalkine blockers in treatment of cancer,” says Thomas Olin, CEO, Kancera.

Selected events within the fractalkine project during the first quarter and until the publication of the interim report

The FRACTAL study of KAND567 in myocardial infarction patients is progressing according to plan. Kancera announces that the Phase IIa clinical trial at Freeman Hospital and James Cook Hospital has recruited and treated 28 of the totally targeted 60 patients to be included in the study. Based on this, we expect to meet the objective to enrol all patients in the study by 2022.

Second generation fractalkine blockers. 28-day toxicological studies of KAND145 have been performed and are currently being analyzed in parallel with the manufacture of the KAND145 product for future clinical trials.

Increased potential for treatment of cancer using fractalkine blockers. Kancera hereby announces new results that show that fractalkine blockers act against treatment-resistant cancer cells through two complementary mechanisms of action. Kancera has previously described the potential for combination therapy with fractalkine blockers and cytostatic drugs. Novel research results support that fractalkine blockers can also act against cancer by inhibiting the tumour’s surrounding support functions, so called nursing cells. Overall, we therefore see an increased potential for Kancera’s drug candidates in the treatment of cancer:

1. The first effect of fractalkine blockers is achieved in combination with cytostatic drugs by accumulating DNA damage. This leads to a more extensive killing of cancer cells even when there are signs of treatment resistance. The primary indication for this treatment is ovarian cancer.

2. The second, and for Kancera newly discovered, is based on the ability of fractalkine blockers to reprogram the microenvironment that normally helps cancer cells to survive, divide and spread. Promising effects of Kancera’s fractalkine blockers are further examined in ongoing studies of patient samples. Results from these studies are planned to be reported during the second half of 2022. The research that forms the basis for this area of use takes place in collaboration with Prof. Håkan Mellstedt and Prof. Anders Österborg at Karolinska Institutet.

About Kancera AB (publ)
Kancera AB is developing a new class of drugs against inflammation and cancer. The company’s drug candidates operate through a newly discovered control system for immune cells and cancer cells, the so-called fractalkine system. Kancera is studying its most advanced drug candidate KAND567 in two fully funded phase IIa clinical trials of heart, kidney and lung injuries caused by hyperinflammation. Top-line data from the phase IIa study in COVID patients were reported in November 2021. Recruitment of patients for the second phase IIa study, of inflammation after myocardial infarction, is expected to be completed in 2022. Kancera also conducts preclinical development of the drug candidate KAND145, which primarily is intended for the treatment of autoimmune diseases and cancer. Kancera also develops preclinical drug candidates against hematological, colorectal and ovarian cancers. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB (info@fnca.se, tel. 08-528 00 399) is the company’s Certified Adviser.

For further information:
Thomas Olin
Chief Executive Officer, Kancera AB
Tel: +46-735-20 40 01

Welcome to visit Kancera’s web page: https://www.kancera.com/en